Report from the 2023 American Society of Hematology Annual Meeting — Benign Hematology

Presenters at the 2023 American Society of Hematology (ASH) annual meeting, held December 9–12 in San Diego, reported the latest research in hematology. NEJM Group was on hand to cover the meeting. Here, NEJM Journal Watch Oncology and Hematology reports on some of the key findings in benign hematology, and Associate Editor Dr. Anjali A. Sharathkumar provides her clinical perspective. Abstracts can be found on the ASH meeting site.

Early Data Show Sickle Hemoglobin Polymerization Inhibitor Effective, Well Tolerated

In adults with sickle cell disease (SCD), the next-generation sickle hemoglobin polymerization inhibitor known as GBT021601 is associated with large increases in mean hemoglobin (Hb) levels and is well tolerated, according to the p…